GSA Capital Partners LLP Acquires Shares of 115,535 NeuroPace, Inc. $NPCE

GSA Capital Partners LLP acquired a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 115,535 shares of the company’s stock, valued at approximately $1,836,000. GSA Capital Partners LLP owned about 0.34% of NeuroPace as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. First Light Asset Management LLC grew its position in shares of NeuroPace by 82.3% during the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock worth $32,349,000 after buying an additional 1,110,484 shares in the last quarter. Lazard Asset Management LLC increased its stake in shares of NeuroPace by 9.8% in the first quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock worth $1,635,000 after buying an additional 11,078 shares during the last quarter. Sei Investments Co. raised its holdings in NeuroPace by 51.4% in the first quarter. Sei Investments Co. now owns 121,476 shares of the company’s stock valued at $1,597,000 after acquiring an additional 41,233 shares in the last quarter. SG Americas Securities LLC raised its holdings in NeuroPace by 52.9% in the first quarter. SG Americas Securities LLC now owns 11,640 shares of the company’s stock valued at $153,000 after acquiring an additional 4,029 shares in the last quarter. Finally, Invesco Ltd. bought a new position in NeuroPace during the 4th quarter valued at $184,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on NPCE shares. Guggenheim reissued a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Mizuho started coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a research report on Wednesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, NeuroPace presently has a consensus rating of “Moderate Buy” and an average target price of $19.29.

NeuroPace Stock Performance

Shares of NPCE opened at $14.77 on Monday. The firm has a fifty day moving average of $15.48 and a 200-day moving average of $15.36. The company has a market cap of $506.91 million, a price-to-earnings ratio of -25.91 and a beta of 1.92. The company has a debt-to-equity ratio of 4.97, a quick ratio of 3.91 and a current ratio of 4.94. NeuroPace, Inc. has a 1 year low of $8.17 and a 1 year high of $19.60.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $22.83 million for the quarter, compared to analysts’ expectations of $22.61 million. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. As a group, equities analysts anticipate that NeuroPace, Inc. will post -0.54 earnings per share for the current year.

NeuroPace Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.